Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Semaglutide DDI with Furosemide and Rosuvastatin
NCT03010475Phase 1Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2017
- Primary completion
- Jun 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Primary endpoints: Area under the furosemide plasma concentration-time curve at Day 54 and Area under the rosuvastatin plasma concentration-time curve at Day 55. Started Jan 2017; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03010475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03010475.